AbbVie entered a warrant agreement with Kestrel funding KST-6051 development plus an exclusive option to acquire Kestrel based on defined development/regulatory milestones; total deal value up to $1.45B across upfront, exercise, and downstream milestone payments. First patient dosed in Phase 1 FALCON trial concurrently announced.